The Cleveland Clinic and Greatbatch Medical- backed neuromodulation device developer is targeting a $9.6m close according to a securities filing.

Roivant Sciences has co-led a $40.5m round for Datavant, an offshoot it launched in August following a $1.1bn round led by SoftBank Vision Fund.

The unit, restructured as a full corporate venturing unit in 2016, has rebranded to M12 while its accelerator counterpart will be known as Microsoft ScaleUp.

University of the West of Scotland's first spinout will deliver ultrasound sensors with the help of a seed round featuring the devolved government-owned Scottish Investment Bank.

The corporate-backed pharmaceutical developers had aimed to raise a total of $155m from offerings they filed for in March.

The reputations of Hebrew University and Hadassah Medical Center are expected to attract private investors as limited partners.

Cambridge Epigenetix has now raised $56.5m from investors including the university and Alphabet’s GV for its epigenetics-powered diagnostic platform.

The Kraft Group-backed spinal muscular atrophy drug developer has raised more than $100m in funding since 2012.

Synthorx's artificial genetic DNA pairings are expected to support the administration of an immuno-oncology drug previously hindered by safety issues.

The Trinity College Dublin spinout is targeting a form of prostate gland enlargement with a device that could be installed in under 15 minutes.